presented an interesting modification to the Model for End-Stage Liver Disease (MELD) score using M-65, a marker of hepatic necrosis, as a substitute for bilirubin in the MELD equation which they subsequently applied to a series of patients with acute liver failure (ALF). The statistical justification and reporting of the subsequent results is useful to discuss.
½MELD score ¼ 9:57 LnðCreatinineÞ þ 3:78 LnðBilirubinÞ þ 11:2 LnðINRÞ þ 6:43 ð1Þ
Creatinine -mg/L, Bilirubin -mg/dL, INR -unitless. Bechmann et al.'s implantation of M-65 into MELD in this ALF cohort is concerning for a number of reasons. Their analysis is based on outcome alone and not the length of survival and therefore uses logistic regression (via Receiver Operating Characteristic (ROC) curves) not proportional hazards. In any multivariate analysis, the independence of predictors must be assessed and M-65, while having a clear univariate correlation with outcome, was not tested against INR and creatinine in a logistic or proportional hazards multivariate model. Furthermore, the effect of INR and creatinine on survival in ALF is likely to be different from cirrhosis; in fact, de novo regression modeling may give different regression coefficients that lead to a more useful MELD improvement rather than the assumption that the regression coefficients from patients with a different disease in a different country are immediately transferable.
Improvements in modeling when assessed by ROC curve analysis can be assessed quantitatively as was lacking in the Bechman et al. analysis. ROC curve comparisons via the Delong method [3] are non-parametric, well validated, and produce a p value for the comparison. While sensitivity and specificity improvements were discussed (again without quantitative comparators) and ROC curves were produced, there was no head to head graphical or quantitative ROC curve comparison between MELD and its modification or comparison among new multivariate models. These would have strengthened the analysis.
Statistical models are not necessarily interchangeable between diseases or populations, and repeat modeling is necessary to provide evidence of validity of the model. Statistical assessment of improvements of multivariate models is available and should be reported to allow the quantitation of the significance of any improvement.
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